Comparing Two CAR-T Therapies: Liso-cel and Axi-cel in LBCL

At a single hospital, patients with large B-cell lymphoma (LBCL) who didn't respond to initial treatments were given either lisocabtagene maraleucel (liso-cel) or axicabtagene ciloleucel (axi-cel). Liso-cel is newer and not widely studied outside clinical trials yet. From June 2021 to September 2022, 50 patients got axi-cel and 37 got liso-cel. Those who received liso-cel were a bit older. It took longer to start treatment with liso-cel (41 days) compared to axi-cel (30 days).

Both therapies showed similar results in making the cancer disappear fully (72% for axi-cel, 62% for liso-cel). However, when considering patient risk factors, liso-cel seemed less effective. Side effects like fever, brain swelling, and prolonged low neutrophil counts were more common with axi-cel. These findings suggest we need more studies to compare these treatments in different hospitals.

Actions